Hyperfine, Inc. reported record revenue of $5.3 million for its fourth quarter of 2025, a 54 % sequential increase from the $3.4 million earned in Q3 and a 127 % year‑over‑year jump from the $2.32 million posted in Q4 2024. The growth was driven by robust demand for the next‑generation Swoop portable MRI system and its accompanying Optive AI software, with new placements in hospital critical‑care units, neurology office settings, and international markets.
Cash and cash equivalents rose to $35.1 million at the end of the quarter, up from $21.6 million in September and from $37.6 million in Q4 2024, giving the company a strong liquidity cushion that extends well into 2026. Operating cash burn improved as sales accelerated and cost controls tightened, allowing the company to maintain a healthy cash runway while investing in product development and market expansion.
Management highlighted the breadth of the quarter’s success. President and CEO Maria Sainz said, “I am very pleased with our record fourth quarter, driven by success across all business verticals with placements in hospitals including technology upgrades, in neurology offices, and international markets.” She added that the company’s “strong market excitement and demand for our next‑generation Swoop® system and Optive AI™ software” enabled rapid deal closures with leading institutions.
Gross margin for the quarter reached 53.8 %, up from 51.2 % in Q3 2025, reflecting a favorable mix of high‑margin AI‑enabled contracts and the scaling of the Swoop platform. Management expects full‑year 2025 gross margins to stay above 50 % as the company continues to expand its AI software portfolio and achieve greater operational leverage.
Hyperfine will provide audited results and detailed guidance in its March 2026 earnings call. The preliminary data suggest a trajectory of accelerating revenue growth, improving profitability, and a solid cash position that supports continued investment in product innovation and market penetration.
The announcement underscores Hyperfine’s progress toward a more sustainable financial profile and signals confidence in its strategy to broaden its customer base beyond hospital critical‑care into neurology office settings and international markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.